Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Capricor Inc. maintains a relatively active patent portfolio in the Biotechnology & Pharmaceuticals technology area with 4 pending office actions. These actions are distributed among 4 distinct examiners, showing a high degree of variety in the individuals reviewing the company's work. Furthermore, the portfolio spans 4 distinct art units. This indicates that the company's research and development efforts are broad, touching on several different specialized areas within biotechnology. Practitioners can see that the workload is widely dispersed across the USPTO's administrative structure.
The busiest examiner for Capricor Inc. is NOBLE, MARCIA STEPHENS, who is managing 1 pending office action. Since there are 4 pending office actions in total, each of the 4 distinct examiners is handling exactly one case. This 1 to 1 ratio between actions and examiners, combined with the 4 distinct art units, suggests a highly diversified prosecution strategy. Practitioners must be prepared to handle four different examiner styles and four sets of art unit guidelines simultaneously. The data reflects a portfolio that is not dependent on any single examiner or art unit for its overall success.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §102 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOBLE, MARCIA STEPHENS | 1 | 67.0% | +39.9% |
| GU, QINHUA | 1 | 75.9% | +27.8% |
| TICHY, JENNIFER M.H. | 1 | 64.9% | +34.5% |
| ZHU, JIANJIAN | 1 | 58.8% | +82.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906464 | CARDIOSPHERE-DERIVED CELL (CDC) THERAPY FOR THE TREATMENT OF VIRAL INFECTIONS | TICHY, JENNIFER M.H. | 53d overdue |
| 17608636 | THERAPEUTICALLY ACTIVE CELLS AND EXOSOMES | ZHU, JIANJIAN | 2d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906464 | CARDIOSPHERE-DERIVED CELL (CDC) THERAPY FOR THE TREATMENT OF VIRAL INFECTIONS | TICHY, JENNIFER M.H. | 53d overdue |
| 18011041 | Extracellular Vesicles Engineered to Be Loaded with Distinct RNA Cargo for Improved Therapeutic Efficacy | GU, QINHUA | 38d overdue |
| 17608636 | THERAPEUTICALLY ACTIVE CELLS AND EXOSOMES | ZHU, JIANJIAN | 2d overdue |
| 18205313 | METHODS AND COMPOSITIONS FOR TREATING SKELETAL MUSCULAR DYSTROPHY | NOBLE, MARCIA STEPHENS | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1633 | 1 |
| 1653 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18205313 | METHODS AND COMPOSITIONS FOR TREATING SKELETAL MUSCULAR DYSTROPHY | NOBLE, MARCIA STEPHENS | 1632 | §102 | Final Rejection | — | Pending | Jun 02, 2023 |
| 18011041 | Extracellular Vesicles Engineered to Be Loaded with Distinct RNA Cargo for Improved Therapeutic Efficacy | GU, QINHUA | 1633 | §103 | Final Rejection | 38d overdue | Pending | Dec 16, 2022 |
| 17906464 | CARDIOSPHERE-DERIVED CELL (CDC) THERAPY FOR THE TREATMENT OF VIRAL INFECTIONS | TICHY, JENNIFER M.H. | 1653 | §102§103 | Final Rejection | 53d overdue | Pending | Sep 15, 2022 |
| 17608636 | THERAPEUTICALLY ACTIVE CELLS AND EXOSOMES | ZHU, JIANJIAN | 1631 | §103§112Other | Final Rejection | 2d overdue | Pending | Nov 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial